Auch bei niedrigem LDL-Cholesterin aggressiv therapieren - Aktueller Stellenwert der Statintherapie beim akuten Koronarsyndrom

Zusammenfassung

Für Personen mit hohem Risiko und Patienten mit „stabiler” koronarer Herzkrankheit ist die Absenkung des LDL-Cholesterins mit Statinen eine empirisch abgesicherte Strategie, um die Inzidenzrate kardiovaskulärer Ereignisse und Todesfälle zu reduzieren. Nachdem es bereits Hinweise gibt, dass eine aggressive Senkung des LDL-Cholesterins die Funktion des Gefäßsystems sehr schnell verbessern könnte, wurde jüngst auch der Einsatz von Statinen bei Patienten mit akutem Koronarsyndrom evaluiert. In der MIRACL[1]-Studie reduzierte die Behandlung mit 80 mg Atorvastatin täglich die Inzidenzrate vaskulärer Ereignisse im Vergleich zu Plazebo bei Patienten mit akutem Koronarsyndrom. Einen erstmaligen direkten Vergleich der Wirkung zweier Statine lieferte PROVE-IT[2]. Dabei war eine intensive Absenkung des LDL-Cholesterinspiegels mit 80 mg Atorvastatin einer moderaten LDL-Reduktion mit 40 mg Pravastatin signifikant überlegen. Entgegen den Erwartungen konnte jedoch eine frühe intensive Therapie mit Simvastatin im Vergleich zu einer verzögert einsetzenden, weniger intensiven Therapie (Studie „A to Z”[3]) keinen statistisch signifikanten Unterschied zwischen den beiden Behandlungsgruppen dokumentieren. Gerade aufgrund des hohen absoluten Risikos der Patienten mit akutem Koronarsyndrom ist dennoch eine aggressive Senkung des LDL-Cholesterins auch noch bei niedrigeren Werten vor der Behandlung gerechtfertigt. Die Wahl der Substanz sollte sich an der Studienlage orientieren.

Zusammenfassung

Lowering LDL cholesterol with statins is an empirically supported strategy to reduce the incidence rate of cardiovascular events and deaths in individuals at high cardiovascular risk and in patients with stable coronary artery disease. As aggressive lowering of LDL may have immediate effects on the function of the vascular system, the use of statins has recently been evaluated in patients with acute coronary syndromes. In the MIRACL study, treatment with 80 mg atorvastatin daily reduced the incidence rate of vascular events compared to placebo in patients with acute coronary syndrome. The PROVE-IT study was the first trial to compare the effects of two statins directly: In this study, an intensive LDL-cholesterol lowering therapy with Atorvastatin (80 mg per day) could outplay a moderate LDL-lowering strategy (40 mg Pravastatin per day) significantly. In the A to Z study early intensive therapy with simvastatin was compared to a delayed less intensive therapy. Unexpectedly, there was no statistically significant difference between the two treatment groups. Given the high absolute risk of the patients with acute coronary syndrome, aggressive LDL lowering is justified in these patients. The choice of the statin should be guided by the evidence available from clinical trials.

Key Words

LDL cholesterol - statins - cardiovascular events - cardio-vascular risk - coronary artery disease

1 myocardial ischemia reduction with aggressive cholesterol lowering

2 pravastatin or atorvastatin evaluation and infection therapy

3 aggrastat to zocor

Literatur

• 1 Anonymous . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.  N Engl J Med. 1998;  339 1349-1357
• 2 Arntz HR, Agrawal R, Wunderlich W. et al. . Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).  Am J Cardiol. 2000;  86 1293-1298
• 3 Aronow HD, Topol EJ, Roe MT. et al. . Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.  Lancet. 2001;  357 1063-1068
• 4 Athyros VG, Papageorgiou AA, Mercouris BR. et al. . Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.  Curr Med Res Opin. 2002;  18 220-228
• 5 Cannon CP, Braunwald E, McCabe CH. et al. . Intensive versus moderate lipid lowering with statins after acute coronary syndromes.  N Engl J Med. 2004;  350 1495-1504
• 6 Davidson MH, Stein EA, Hunninghake DB. et al. . Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.  Nutr Metab Cardiovasc Dis. 2000;  10 253-262
• 7 de Lemos JA, Blazing MA, Wiviott SD. et al. . Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.  JAMA. 2004;  292 1307-1316
• 8 Downs J, Clearfield M, Weis S. et al. . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA. 1998;  279 1615-1622
• 9 Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
• 10 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 7-22
• 11 Kayikcioglu M, Torkoglu C, Kultursay H. et al. . The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarctions.  Circulation. 1999;  100 I-303
• 12 Kleemann R, Verschuren L, de Rooij BJ. et al. . Evidence for anti-inflammatory activity of statins and PPAR alpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.  Blood. 2004;  103 4188-4194
• 13 Liem A, van Boven AJ, Withagen AP. et al. . Fluvastatin in acute myocardial infarction: effects on early and late ischemia and events: the FLORIDA trial.  Circulation. 2000;  102 2672
• 14 März W, Winkler K, Nauck MS. et al. . Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study).  Am J Cardiol. 2003;  92 305-308
• 15 Nissen SE, Tuzcu EM, Schoenhagen P. et al. . Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.  JAMA. 2004;  291 1071-1080
• 16 Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels.  Jama. 2004;  292 1365-1367
• 17 Pedersen TR, Olsson AG, Faergeman O. et al. . Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S).  Circulation. 1998;  97 1453-1460
• 18 Pitt B, Waters D, Brown WV. et al. . Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.  N Engl J Med. 1999;  341 70-76
• 19 Ridker PM, Cannon CP, Morrow D. et al. . C-reactive protein levels and outcomes after statin therapy.  N Engl J Med. 2005;  352 20-28
• 20 Sacks F, Moye LA, Davis BR. et al. . Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.  Circulation. 1998;  97 1446-1452
• 21 Sacks FM, Pfeffer MA, Moye LA. et al. . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.  N Engl J Med. 1996;  335 1001-1009
• 22 Schwartz GG, Olsson AG, Ezekowitz MD. et al. . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.  JAMA. 2001;  285 1711-1718
• 23 Shepherd J, Cobbe SM, Ford I. et al. . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.  N Engl J Med. 1995;  333 1301-1307
• 24 Simes R, Marschner IC, Hunt D. et al. . LIPID Study Investigators: Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?.  Circulation. 2002;  105 1162-1169
• 25 Smilde TJ, van Wissen S, Wollersheim H. et al. . Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial.  Lancet. 2001;  357 577-581
• 26 Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival.  JAMA. 2001;  285 430-436
• 27 Taylor AJ, Kent SM, Flaherty PJ. et al. . ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.  Circulation. 2002;  106 2055-2060

1 myocardial ischemia reduction with aggressive cholesterol lowering

2 pravastatin or atorvastatin evaluation and infection therapy

3 aggrastat to zocor

4 global use of strategies to open occluded coronary arteries

5 platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy

6 fluvastatin on risk diminishing after acute myocardial infarction

7 heart protection study

8 cholesterol and recurrent events

9 scandinavian simvastatin survival study

Anschrift des Verfassers